All In Biotech

Drug Trial Radar · NCT07852091

A Novel Combination Therapeutic Strategy Aiming to Functional Cure for Chronic Hepatitis B Virus Infection (A)

Last checked: Nov 19, 2026Latest source record: Oct 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

1,200

Planned (sponsor's estimate)

Start

Oct 10, 2023

Primary completion

Dec 31, 2026

Study completion Dec 31, 2026

Sponsor

Sponsor type
Academic, hospital or other
Collaborators
The Affiliated Hospital Of Southwest Medical University; Guizhou Provincial People's Hospital; Chongqing Three Gorges Central Hospital; First Affiliated Hospital of Chongqing Medical University
First posted
Oct 1, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Hepatitis B virus (HBV) infection is a major public health threat in China. At present, a functional cure, also known as clinical cure or sustained Hepatitis B surface antigen (HBsAg) loss, is recommended as the ideal endpoint of HBV treatment. However, HBsAg loss can be achieved in less than 10% of chronic hepatitis B (CHB) patients treated with current available antiviral drug interferonα (IFNα) or nucleos(t)ide analogues (NAs) monotherapy. With the support of the national major special funding for infectious diseases from "11th Five-Year Plan" to "13th Five-Year Plan", we have implemented a pioneer clinical study of sequential combination of IFNα therapy on NAs to treat NAs-treated CHB patients (ie. New Switch Study). This is the world's first clinical trial aiming to functional cure, which increased the rate of HBsAg loss to 15% in the overall population in our study, and to 30-50% among those with lower baseline HBsAg levels. How to further improve the HBsAg loss rate is an urgent issue for us. The key point of achieving functional cure is to reverse the HBV-specific T cell exhaustion and establish the long-term immune control against HBV infection. Programmed death-1(PD-1)/programmed death-ligand 1 (PD-L1) axis blockade has been demonstrated to reinvigorate exhausted CD8+ T cells, and would be a potential strategy to treat chronic HBV infection. In this study, a large multicenter prospective study will be performed to explore the safety and efficacy of a novel combination strategy involving immune checkpoint inhibitor (anti-PD-1/anti-PD-L1 antibody) and IFNα in CHB patients, observe the HBsAg loss rate in NA-treated CHB patients receiving this combination strategy, evaluate the potential of breaking immune tolerance by this strategy, and further assess its efficacy to further improve the clinical cure rate on the basis of New Switch Study. Based on New Switch Study, this study further attempts to reverse T cell exhaustion in CHB patients, explore a novel platform of combination therapy development for clinical cure, and ultimately increase the HBsAg loss rate to higher than 50% in overall patients. The implementation of the project is expected to reduce the burden of HBV infection in China and contribute to the goal of global elimination of hepatitis B and C by 2030 (WHO 2030).

Conditions

  • Chronic Hepatitis B

Interventions

  • Sintilimab/EnvafolimabDrug

    Sintilimab(anti-PD-1 antibody),once/three weeks, dose lower than the dose used in cancer patients, intravenous injection; Envafolimab(anti-PD-L1 antibody),once/two weeks, dose lower than the dose used in cancer patients, subcutaneous injection

  • ETV/TDF/TAFDrug

    NAs(ETV/TDF/TAF), Once/day, 1 capsule/time, oral

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Serum HBsAgTime frame: Baseline
  2. Serum HBsAgTime frame: 24 weeks after the treatment
  3. Serum HBsAgTime frame: 48 weeks after the treatment
  4. Serum HBsAgTime frame: 24 weeks after the end of treatment
  5. Serum HBV DNATime frame: Baseline
  6. Serum HBV DNATime frame: 24 weeks after the treatment
  7. Serum HBV DNATime frame: 48 weeks after the treatment
  8. Serum HBV DNATime frame: 24 weeks after the end of treatment
  9. Serum alanine aminotransferase (ALT)Time frame: Baseline
  10. Serum alanine aminotransferase (ALT)Time frame: 24 weeks after the treatment
  11. Serum alanine aminotransferase (ALT)Time frame: 48 weeks after the treatment
  12. Serum alanine aminotransferase (ALT)Time frame: 24 weeks after the end of treatment

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The 2nd affiliated Hospital of Chongqing Medical University

    Chongqing, Chongqing Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.